Funck et al., 2020 - Google Patents
Human innate immune cell crosstalk induces melanoma cell senescenceFunck et al., 2020
View PDF- Document ID
- 5189637101577745388
- Author
- Funck F
- Pahl J
- Kyjacova L
- Freund L
- Oehrl S
- Gräbe G
- Pezer S
- Hassel J
- Sleeman J
- Cerwenka A
- Schäkel K
- Publication year
- Publication venue
- Oncoimmunology
External Links
Snippet
Mononuclear phagocytes and NK cells constitute the first line of innate immune defense. How these cells interact and join forces against cancer is incompletely understood. Here, we observed an early accumulation of slan+ (6-sulfo LacNAc) non-classical monocytes …
- 210000004027 cells 0 title abstract description 172
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chong et al. | Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy | |
Tobin et al. | IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients | |
Zappasodi et al. | Rational design of anti-GITR-based combination immunotherapy | |
Lin et al. | Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer | |
Yang et al. | Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity | |
Cohen et al. | B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma | |
Gunderson et al. | TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking | |
Meyer et al. | Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance | |
Galletti et al. | Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression | |
Huang et al. | Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer | |
Gómez-Aleza et al. | Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells | |
Frassanito et al. | Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis | |
Guan et al. | Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML) | |
Roda et al. | Natural killer cells produce T cell–recruiting chemokines in response to antibody-coated tumor cells | |
Chen et al. | Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia | |
Kohrgruber et al. | Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands | |
Djudjaj et al. | Macrophage migration inhibitory factor mediates proliferative GN via CD74 | |
Vallejo et al. | Synoviocyte-mediated expansion of inflammatory T cells in rheumatoid synovitis is dependent on CD47-thrombospondin 1 interaction | |
Wang et al. | EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway | |
Gordin et al. | c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74 | |
Olivera et al. | A therapeutically actionable protumoral axis of cytokines involving IL-8, TNFα, and IL-1β | |
Cheong et al. | Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo | |
Grotz et al. | Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma | |
Picchio et al. | CXCL13 is highly produced by Sezary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines | |
Castiglioni et al. | Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors |